Role of serum B-cell-activating factor and interleukin-17 as biomarkers in the classification of interstitial pneumonia with autoimmune features

被引:2
|
作者
Zhao, Lihong [1 ]
Liu, Li [1 ]
Liu, Yehua [2 ]
Zheng, Hong [1 ]
Jiang, Ping [1 ]
机构
[1] Tianjin First Cent Hosp, Dept Resp & Crit Care Med, 24 Fukang Rd, Tianjin 300192, Peoples R China
[2] Tianjin First Cent Hosp, Dept Clin Lab, Tianjin 300192, Peoples R China
来源
OPEN LIFE SCIENCES | 2024年 / 19卷 / 01期
关键词
interstitial lung disease; pneumonia autoimmune features; BAFF; interleukin-17; inflammatory mechanism; CRITERIA; LUNG; COLLEGE; LEAGUE;
D O I
10.1515/biol-2022-0814
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Interstitial pneumonia with autoimmune features (IPAF) is a type of interstitial lung disease (ILD) with immune features that do not meet the diagnostic criteria for specific connective tissue diseases (CTDs). This retrospective case-control study investigated the role of serum B-cell-activating factor of the tumor necrosis factor family (BAFF) and interleukin (IL)-17 as biomarkers for IPAF. The differences in serum BAFF, IL-17, and IL-10 were compared among patients with idiopathic pulmonary fibrosis (IPF), IPAF, ILD associated with CTD (CTD-ILD), and healthy controls. The patients were treatment naive. The correlations of BAFF with IL-10, IL-17, and pulmonary function were analyzed. The classifiable value of BAFF for IPAF was examined. The results showed that the serum levels of BAFF and IL-17 in the IPAF and CTD-ILD groups were higher than in the IPF group. High BAFF levels and high predicted diffusion capacity of the lungs for carbon monoxide (DLCO) were independent predictive factors for IPAF vs IPF. In the IPAF and CTD-ILD groups, serum BAFF levels were negatively correlated with predicted values of forced vital capacity (FVC%) and diffusing capacity of the lungs for carbon monoxide (DLCO%) and positively correlated with serum IL-17 and IL-10 levels. The cutoff value of combined BAFF and IL-17 was 0.704, and the sensitivity and specificity for classifying IPAF were 78.9 and 95.7%, respectively. In conclusion, combining serum BAFF and IL-17 as a biomarker may have classifiable value in differentiating IPAF from other forms of ILD.
引用
收藏
页数:10
相关论文
共 50 条
  • [31] Serum B-cell activating factor and lung ultrasound B-lines in connective tissue disease related interstitial lung disease
    Wang, Yukai
    Xie, Xuezhen
    Zheng, Shaoyu
    Du, Guangzhou
    Chen, Shaoqi
    Zhang, Weijin
    Zhuang, Jinghua
    Lin, Jianqun
    Hu, Shijian
    Zheng, Kedi
    Mikish, Angelina
    Xu, Zhuangyong
    Zhang, Guohong
    Gargani, Luna
    Bruni, Cosimo
    Hoffmann-Vold, Anna-Maria
    Matucci-Cerinic, Marco
    Furst, Daniel E. E.
    FRONTIERS IN MEDICINE, 2022, 9
  • [32] RETRACTED: Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus (Retracted Article)
    Doreau, Agnes
    Belot, Alexandre
    Bastid, Jeremy
    Riche, Benjamin
    Trescol-Biemont, Marie-Claude
    Ranchin, Bruno
    Fabien, Nicole
    Cochat, Pierre
    Pouteil-Noble, Claire
    Trolliet, Pierre
    Durieu, Isabelle
    Tebib, Jacques
    Kassai, Berhouz
    Ansieau, Stephane
    Puisieux, Alain
    Eliaou, Jean-Francois
    Bonnefoy-Berard, Nathalie
    NATURE IMMUNOLOGY, 2009, 10 (07) : 778 - U142
  • [33] Interleukin-17 levels correlate with poor prognosis and vascular endothelial growth factor concentration in the serum of patients with non-small cell lung cancer
    Pan, Bo
    Che, Dehai
    Cao, Jingyan
    Shen, Jing
    Jin, Shi
    Zhou, Yongxu
    Liu, Fang
    Gu, Kuo
    Man, Yingchun
    Shang, Lihua
    Yu, Yan
    BIOMARKERS, 2015, 20 (04) : 232 - 239
  • [34] Serum tumor necrosis factor-α, interleukin-1β, interleukin-6, and interleukin-17 relate to anxiety and depression risks to some extent in non-small cell lung cancer survivor
    Liu, Meifang
    Li, Yao
    Liu, Xuesong
    CLINICAL RESPIRATORY JOURNAL, 2022, 16 (02): : 105 - 115
  • [35] Increased Serum B Cell Activating Factor and a Proliferation-inducing Ligand Are Associated with Interstitial Lung Disease in Patients with Juvenile Dermatomyositis
    Kobayashi, Norimoto
    Kobayashi, Ichiro
    Mori, Masaaki
    Sato, Shinji
    Iwata, Naomi
    Shigemura, Tomonari
    Agematsu, Kazunaga
    Yokota, Shumpei
    Koike, Kenichi
    JOURNAL OF RHEUMATOLOGY, 2015, 42 (12) : 2412 - 2418
  • [36] Elevated serum B cell activating factor belonging to the TNF family (BAFF) in interstitial lung diseases associated with collagen vascular disease
    Hamada, Tsutomu
    Takuya, Samukawa
    Mizuno, Keiko
    Higashimoto, Ikkou
    Inoue, Hiromasa
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [37] B-cell activating factor/Th17/Neutrophils axis plays a role in refractory nasal polyposis
    Kim, Dong-Kyu
    Ryu, Gwanghui
    Hong, Sang Duk
    Kong, Il Gyu
    Chung, Seung Kyu
    Lee, Jae Seo
    Dhong, Hun Jong
    Kim, Dae Woo
    JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2018, 141 (02) : AB90 - AB90
  • [38] Gingival Crevicular Fluid, Serum Levels of Receptor Activator of Nuclear Factor-κB Ligand, Osteoprotegerin, and Interleukin-17 in Patients With Rheumatoid Arthritis and Osteoporosis and With Periodontal Disease
    Gumus, Pinar
    Buduneli, Eralp
    Biyikoglu, Basak
    Aksu, Kenan
    Sarac, Fulden
    Nile, Christopher
    Lappin, David
    Buduneli, Nurcan
    JOURNAL OF PERIODONTOLOGY, 2013, 84 (11) : 1627 - 1637
  • [39] Interleukin 17 acts in synergy with B cell-activating factor to influence B cell biology and the pathophysiology of systemic lupus erythematosus (vol 10, pg 778, 2009)
    Doreau, Agnes
    Belot, Alexandre
    Bastid, Jeremy
    Riche, Benjamin
    Trescol-Biemont, Marie-Claude
    Ranchin, Bruno
    Fabien, Nicole
    Cochat, Pierre
    Pouteil-Noble, Claire
    Trolliet, Pierre
    Durieu, Isabelle
    Tebib, Jacques
    Kassai, Berhouz
    Ansieau, Stephane
    Puisieux, Alain
    Eliaou, Jean-Francois
    Bonnefoy-Berard, Nathalie
    NATURE IMMUNOLOGY, 2014, 15 (09) : 894 - 894
  • [40] Circulating B-cell activating factor of the tumour necrosis family (BAFF) and interleukin 21 levels predict treatment response in patients with autoimmune hepatitis
    Biewenga, Maaike
    Heidt, Sebastiaan
    Vergunst, Manon
    Marijnissen, Camiel
    Van der Meer, Adriaan
    De Man, Robert
    Van der Eijk, Annemiek
    Trouw, Leendert
    Van Hoek, Bart
    JOURNAL OF HEPATOLOGY, 2021, 75 : S428 - S428